Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding
It is very uncertain whether gnRH analogues changes postoperative amenorrhoea at 12 months or less compared with placebo or no treatment (very low certainty).
1 finding from 1 review
RR 1.58 [1.24, 2.01]
605 participants
Very low
Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding
It is very uncertain whether gnRH analogues changes postoperative amenorrhoea at 12 months or less compared with danazol (very low certainty).
1 finding from 1 review
RR 1.17 [0.9, 1.52]
340 participants
Very low
Postoperative amenorrhoea at 12 months or less · women with heavy menstrual bleeding
It is very uncertain whether gnRH analogues changes postoperative amenorrhoea at 12 months or less compared with progestogens (very low certainty).
1 finding from 1 review
RR 1.58 [0.96, 2.61]
146 participants
Very low
Endometrial cancer · Women treated with ovary‐stimulating drugs for subfertility
It is very uncertain whether exposure to GnRH analogues for subfertility changes endometrial cancer compared with untreated subfertile women and endometrial cancer risk (very low certainty).
1 finding from 1 review
GnRHas vs gestrinone Percentage change values ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
2 findings from 1 review
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Anterior‐posterior spine ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
1 finding from 1 review
GnRHas vs GnRHas in conjunction with calcium‐regulating agents Lateral spine ‐ 12 months · Women with endometriosis, treated with GnRHas with effect on bone mineral density
1 finding from 1 review
Quality of life · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bone density (SMD) ‐ · patients with uterine fibroids
1 finding from 1 review
Uterine size (cm3) ‐ · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uterine bleeding · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of vasomotor symptoms · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of vasomotor symptoms ‐ · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uterine bleeding · patients with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of vasomotor symptoms · patients with uterine fibroids
1 finding from 1 review
Rate of vasomotor symptoms ‐ · patients with uterine fibroids
GnRH‐a + tibolone showed no clear difference in rate of vasomotor symptoms ‐ compared with gnRH‐a ± placebo (low certainty).
1 finding from 1 review
QoL · patients with uterine fibroids
1 finding from 1 review
Bone density (SMD) ‐ · patients with uterine fibroids
1 finding from 1 review
Uterine size (cm3) ‐ · patients with uterine fibroids
1 finding from 1 review
QoL · patients with uterine fibroids
1 finding from 1 review